Table 3 Characteristics of patients without clinical complete response
5-FU+MMC ( n =5) | Capecitabine+MMC ( n =6) | ||||
---|---|---|---|---|---|
Characteristic | No. | % | No. | % | P -value |
Age (years), median (range) | 65.6 (36.8–73.5) | 56.2 (41.3–65.1) | 0.545 | ||
Gender | |||||
Male | 3 | 60 | 5 | 83 | 0.559 |
Female | 2 | 40 | 1 | 17 | |
T-classification | |||||
T1 | 0 | 0 | 0 | 0 | 0.177 |
T2 | 2 | 40 | 0 | 0 | |
T3 | 2 | 40 | 3 | 50 | |
T4 | 1 | 20 | 3 | 50 | |
N-classification | |||||
N0 | 2 | 40 | 1 | 17 | 0.086 |
N1 | 1 | 20 | 0 | 0 | |
N2 | 2 | 40 | 2 | 33 | |
N3 | 0 | 0 | 3 | 50 | |
HIV status | |||||
Negative | 0 | 0 | 4 | 67 | 0.333 |
Positive | 1 | 20 | 1 | 17 | |
Not known | 4 | 80 | 1 | 17 | |
Primary tumor site | |||||
Anal canal | 6 | 100 | 6 | 100 | 1.000 |
Anal margin | 0 | 0 | 0 | 0 | |
Both | 0 | 0 | 0 | 0 |